Skip to content

About
Science
- Overview
- Publications
Pipeline
Investors
Careers
Contact

About
Science
- Overview
- Publications
Pipeline
Investors
Careers
Contact

Press Releases

Choose Year
Search Press Releases

Found 83 Results

May 9, 2025

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

March 31, 2025

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 24, 2025

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

November 6, 2024

Surrozen to Present at Upcoming Healthcare Investor Conferences

November 6, 2024

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

November 4, 2024

Surrozen and TCGFB,Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

September 24, 2024

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

August 12, 2024

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

June 12, 2024

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology,to Further Enhance Wnt Signaling

June 10, 2024

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

«123 4 5...»

IR Contact

Email: investorinfo@surrozen.com

Email Alerts Sign-Up

Email

Unsubscribe

Loading...

Company

About
Management
Board of Directors
Scientific Advisors
Contact
Careers

Science

Science
Pipeline
Publications

Investors

Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

Copyright © 2026 Surrozen. All Rights Reserved

FCOI Policy
Accessibility

Scroll to Top